Atila PGx Core Drug Metabolism SNP Panel (ADME Backbone)
Genotyping of 29 SNPs across 6 core ADME genes for broad Phase I/II drug-metabolism coverage.
Each kit includes 100 tests. This product is for Research Use Only (RUO).
Atila PGx Core Drug Metabolism SNP Panel (ADME Backbone)
A general-purpose metabolism backbone covering the enzymes that process the majority of prescribed drugs. CYP3A4/CYP3A5 handle a broad substrate range (CYP3A5 is CPIC-guided for tacrolimus dosing); CYP1A2 and CYP2C9 add major Phase I coverage (NSAIDs, phenytoin, clozapine, theophylline); and EPHX1 and UGT2B15 extend into detoxification and Phase II glucuronidation. Designed to complement the therapeutic-area panels or stand alone as a foundational ADME screen.
Features Include
Technical Specs
Workflow Overview for the Atila PGx Core Drug Metabolism SNP Panel (ADME Backbone)
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
Prepare the sample–master mix
For each sample, combine 2 µL of PCR master mix with 1 µL of genomic DNA to make a 3 µL-per-reaction mix. Scale the volume to the number of assay wells required for that sample.
Load the panel plate
Dispense the combined master mix–sample mixture into each assay well of the pre-arrayed panel plate. Seal the plate and briefly centrifuge to collect the reaction at the bottom of each well.
Run real-time PCR
Load the plate onto a Bio-Rad CFX or Applied Biosystems Quant Studio real-time PCR system and run the standard PCR cycling protocol.
Data analysis
Import the run file into the accompanying analysis software for automated allele calling and genotype determination across all panel SNPs.
Obtain result report
The software generates a structured pharmacogenetics report translating each genotype into gene-level phenotype and drug-response context.